SCHEMBL13614825

SCHEMBL13614825

Cc1cccc2nc(-c3ccc(-c4c5ccccc5cc5ccccc45)cc3)c(-c3ccc(-c4c5ccccc5cc5ccccc45)cc3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
PDE10A Q9Y233 1/20 0.43
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ESR1 P03372 3/20 0.40
ESR2 Q92731 3/20 0.40
ALOX5 P09917 1/20 0.40
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
ATM Q13315 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP2A6 P11509 1/20 0.37
DHODH Q02127 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341001 0.83 ALOX5 (0.50) MAPTPDE10ATDP1ALDH1A1HPGD
SCHEMBL13614908 0.80 ALOX5 (0.47) PDE10ATDP1ALDH1A1ESR1ESR2
SCHEMBL12578244 0.80 MAPT (0.58) MAPTMAPK1RAB9APDE10ATDP1
SCHEMBL28079390 0.78 PDE10A (0.51) MAPTMAPK1RAB9APDE10ATDP1
SCHEMBL13614817 0.78 ESR1 (0.51) MAPK1TDP1ALDH1A1ESR1ESR2
SCHEMBL13614824 0.78 ALOX5 (0.49) MAPTALDH1A1HPGDHSD17B10ESR1
SCHEMBL14143762 0.75 MAPT (0.50) MAPTMAPK1RAB9APDE10ATDP1
SCHEMBL11947026 0.75 MAPK1 (0.45) MAPTMAPK1RAB9APDE10ATDP1
SCHEMBL11947015 0.74 MAPT (0.44) MAPTMAPK1RAB9APDE10ATDP1
SCHEMBL11946999 0.74 MAPT (0.49) MAPTMAPK1RAB9APDE10ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612204-B2 Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-11-03 US disclosed
US-7612204-B2 Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-11-03 US disclosed
WO-2008047589-A1 QUINOXALINE DERIVATIVE, AND LIGHT-EMITTING ELEMENT AND LIGHT-EMITTING DEVICE USING QUINOXALINE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-24 WO disclosed
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-17 US disclosed
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080091012-A1 Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative NQO1, GLB1, PDXK MAPT 3757/4885MAPK1 1834/4885RAB9A 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.